Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 4 of the last 4 fiscal years.
-
Tight liquidity NBB
Cash and receivables cover 15 % of short-term debt in 2026; threshold 65 %.
Financials
Financial year 2026
Beisol Pharma Poederlee from Lubbeek, company number BE0544651040, closed financial year 2026 with a result of € 7,573 after tax. For that financial year Beisol Pharma Poederlee recorded revenue of € 16,680 and equity of € -59,419. Compared with financial year 2025, the result moved from € 9,218 to € 7,573. The company is profitable. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on October 5, 2026.
€ -59,419
▲ € 7,573 vs 2025
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 7,573
▼ 18% vs 2025
Profit after tax over the fiscal year.
€ 78
▼ 72% vs 2025
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2026. Retained profit grew to € -65,619.
Debts at end 2026
None
No bank loans on the last day of the fiscal year.
| 2023 | 2024 | 2025 | 2026 | Change 2025 → 2026 | |
|---|---|---|---|---|---|
| Revenue | € 37,530 | € 37,530 | € 16,680 | € 16,680 | |
| Gross margin | € 23,417 | € 27,359 | € 9,635 | € 8,040 | ▼ 17% |
| Profit after taxes | € -23,824 | € -16,966 | € 9,218 | € 7,573 | ▼ 18% |
| Equity | € -59,242 | € -76,209 | € -66,992 | € -59,419 | ▲ € 7,573 |
| Total debts | € 206,131 | € 190,185 | € 172,592 | € 159,033 | ▼ 8% |
| Cash | € 138 | € 14 | € 277 | € 78 | ▼ 72% |
| Retained profit | € -65,442 | € -82,409 | € -73,192 | € -65,619 | ▲ € 7,573 |
| Balance sheet total | € 146,889 | € 113,976 | € 105,600 | € 99,614 | ▼ 6% |
Key figures of Beisol Pharma Poederlee, fiscal years 2023 to 2026, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2027) expected before 31 October 2027.
What happened to Beisol Pharma Poederlee?
What happened at Beisol Pharma Poederlee in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2026: profit of € 7,573 (▼ 18% vs 2025). Source: NBB ↗
- New establishment in Lubbeek. KBO
- Start of the company according to the CBE. KBO
In short
From € 23,824 loss in 2023 to € 7,573 profit in 2026.
Best year ever: 2025, with € 9,218 profit.
Establishments
Establishment units
Physical locations of this company
Staatsbaan(LUB) 187
3210 Lubbeek
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 8 companies are registered at this address.
All companies at this address →KULAPRO
€ 2.7 million revenue · 2025
CRAYNWINKEL
€ 366,044 revenue · 2025
Beisol Pharma Tienen
€ 11,200 revenue · 2026
Beisol Pharma Kortenberg
€ 26,900 revenue · 2026
Beisol Pharma Meerle
€ 20,480 revenue · 2026
+3 more
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0544.651.040
- VAT number
- BE 0544.651.040
- Registered office
- Staatsbaan(LUB) 187, 3210 Lubbeek
- Names & denominations
- Beisol Pharma Poederlee
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 22 January 2014
- Peppol
- Active · Active since 19 Dec 2025
- Contact
- [email protected] 016622141
- Activities · NACE
Lease van intellectuele eigendom en vergelijkbare producten, met uitzondering van werken onder auteursrecht